A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

By D. Siegel, T. Martin, Michael L. Wang, R. Vij, A. Jakubowiak, S. Lonial, S. Trudel, V. Kukreti, N. Bahlis, M. Alsina and 13 more. Blood, 2012

633 citations recorded by the source corpus.